Boehringer Ingelheim Corporation's Afatinib Shows Benefits for EGFR Mutation Positive Non-Small Cell Lung Cancer Patients Across Various Efficacy Endpoints

Published: Aug 01, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Afatinib* shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints

INGELHEIM, Germany--(BUSINESS WIRE)-- Data from the LUX-Lung clinical trial programme, investigating afatinib in patients with advanced non-small cell lung cancer (NSCLC), have been published in the Journal of Clinical Oncology. These data include results from the pivotal LUX-Lung 3 Phase III registration trial which show that afatinib delays tumour growth and improves disease-related symptoms and quality of life compared to standard chemotherapy, when used to treat patients with EGFR mutation positive NSCLC.

Help employers find you! Check out all the jobs and post your resume.

Back to news